



The *in ovo* model as a potential alternative to rodents for CRC research



<u>Benčurová K</u>^{1,2}, Coban M^{1,2,3}, Leipold M^{1,2,3}, Mayrhofer M⁴, Zacher A², Ponti S², Friske J⁵, Helbich T⁵, Tran L^{1,6}, Egger G^{1,6}, Hacker M², Haug A², Mitterhauser M^{1,2,7}, Balber T^{1,2}

¹ Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria, ² Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ³ University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria, ⁴ University of Applied Sciences Upper Austria, Wels, Austria, ⁵ Division of General Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶ Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁷ Department for Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Vienna, Austria

Objective

Development of novel radiotracers for cancer research involves costly and time-demanding animal testing. In accordance with the 3R principle¹, rodents can be replaced by immature forms of non-mammalian vertebrates, such as chick embryos (*in ovo*). We aimed at establishing this model for colorectal cancer (CRC) with the focus on C-X-C motif chemokine receptor type 4 (CXCR4) expression, as this receptor is of prognostic value for CRC^{2,3}.



Protocols for incubation, tumor cell inoculation (Fig. 1), *i.v.* injection and anaesthesia were optimized. Immunohistochemical (IHC) analysis using an antibody against desmin proved vascularization of the grafts (Fig. 2B). Staining of cells of epithelial origin (cytokeratin 19 IHC) differentiated between the inoculated cancer cells and the CAM (Fig. 2C). µMRI showed superior soft tissue contrast compared to µCT (Fig. 3). Tumor accumulation of the radiolabeled glucose-analogue, [¹⁸F]FDG (Fig. 4), indicated glucose turnover and viability of the grafts. The latter was proven with IHC (ki67, cleaved caspase 3) (Fig. 2D,E). Preliminary results showed accumulation of [⁶⁸Ga]Ga-Pentixafor, PET-tracer targeting CXCR4, in xenografts derived from HT29 and HCT116 cells (Fig. 5A,D). Specificity was shown by co-injection of an excess of CXCR4 Antagonist I (blocking) (Fig. 5B,D). Target expression was confirmed immunohistochemically (Fig. 2F).

Α

В

C





Figure 1: optimization of the *in ovo* model for CRC research

Temperature and duration of storage of chicken eggs prior to incubation influenced development of chick embryos (A). There was no significant difference when cleaning the egg shell using sterile, distilled water or 70% ethanol prior to start of incubation (B). Using HCT116, EDD9 was identified as an ideal day for inoculation of CRC cells (C).



Figure 3: *in ovo* μ **CT vs.** μ **MRI** CT image (80kV, 500 μ A) of EDD16 chick embryo performed 60 min after application of iodinated contrast agent lomeron into albumen (A). Delineation of xenograft based on μ CT is not possible; organs cannot be distinguished. In comparison MRI image (T2w, TurboRARE) of an EDD16 chick embryo

(B). Xenografts are indicated with an arrow.



Figure 4: [¹⁸F]FDG uptake in CAMxenografts

MR image fused with [¹⁸F]FDG PET. CAMxenograft grown from HT29 (A) or HCT116 cells (B) is indicated with an arrow. The μ PET static measurement was performed for 30 min starting at 60 min *p.i.* of 4.7 MBq (A) or 48 min *p.i.* of 8.1 MBq (B) [¹⁸F]FDG at EDD14 (A) or EDD13 (B).



Figure 2: characterization of HCT116 and HT29 xenografts grown on the CAM

HCT116 (upper row) and HT29 (lower row) CAM-xenografts were characterized using H&E stain (A, ($n \ge 9$)). IHC analysis was performed using antibody against desmin (B, pericytes in the vascular network ($n \ge 3$)), cytokeratin 19 (C, epithelial cells ($n \ge 3$)), ki67 (D, proliferating cells ($n \ge 3$)), cleaved caspase 3 (E, apoptotic cells ($n \ge 3$)), CXCR4 (F, target of interest ($n \ge 3$)). Magnification: 200-fold.



Conclusion

These results show the potential of the *in ovo* model for investigating radiotracer accumulation in xenografts derived from CRC cell lines. The model may lead to reduction of animal experiments in the future. As a step towards novel precision medicine concept, we aim to implant patient-derived organoids.

References

¹ Russell WMS, Burch RL. The principles of humane experimental technique. [Reissued: 1992, Universities Federation for Animal Welfare, Potters Bar, Herts., UK] Special ed. London: Methuen; 1959

² Kim J, Takeuchi H, Lam ST, *et al.* Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. *J Clin Oncol.* 2005;23(12):2744-2753. doi: 10.1200/JCO.2005.07.078

³ Xu C, Zheng L, Li D, *et al.* CXCR4 overexpression is correlated with poor prognosis in colorectal cancer. *Life Sci.* 2018;208:333-340. doi: 10.1016/j.lfs.2018.04.050

⁴ Murakami T, Kawada K, Iwamoto M, *et al.* The role of CXCR3 and CXCR4 in colorectal cancer metastasis. *Int J Cancer*. 2013;132(2):276-287. doi: 10.1002/ijc.27670

Figure 5: [⁶⁸Ga]Ga-Pentixafor uptake in CAM-xenografts and organs of chick embryo

MR image only (lower row) or fused with [⁶⁸Ga]Ga-Pentixafor PET (upper row) with (B) or without (A,C) blocking using CXCR4 Antagonist I (AMD3100). CAM-xenograft grown from HT29 cells is indicated with an arrow (A,B). C: Representative image of [⁶⁸Ga]Ga-Pentixafor uptake in chick embryo organs. Axial view (A,B,C). The µPET static measurement was performed for 30 min starting at 60 min *p.i.* of 3.5 MBq (A,C) or 7.6 MBq (B) [⁶⁸Ga]Ga-Pentixafor at EDD15 (A,C) or EDD16 (B). [⁶⁸Ga]Ga-Pentixafor uptake in HT29 and HCT116 xenografts 60 min. *p.i.* (D, (n=1)) and in organs of chick embryo 60 min *p.i.* (E, (n=2-3)).